Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.17)
# 1,050
Out of 4,829 analysts
110
Total ratings
35.58%
Success rate
3.68%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $1.53 | +4,148.37% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.83 | +1,344.74% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.51 | +1,025.83% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.02 | +978.43% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $39.42 | +26.84% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.22 | +1,293.44% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.25 | +8,551.20% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $1.77 | +5,945.20% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.30 | +4,549.62% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.53 | +4,279.08% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.22 | +1,836.94% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.05 | +197.52% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.95 | +687.32% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.39 | +979.14% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $6.15 | +241.46% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $3.79 | +902.64% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.83 | +4,713.48% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.55 | +809.09% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $7.05 | +1,517.02% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $2.63 | +7,504.56% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $10.38 | +217.92% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $17.30 | +131.21% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $0.91 | +4,275.89% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.80 | +1,955.56% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $3.66 | +774.32% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $10.98 | +601.28% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.73 | +9,489.04% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.45 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $13.03 | +283.73% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $2.19 | +1,406.85% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.41 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $6.18 | +320.71% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $132.18 | -78.82% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.27 | +16,029.03% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $7.06 | +197.45% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $1.53
Upside: +4,148.37%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.83
Upside: +1,344.74%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.51
Upside: +1,025.83%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.02
Upside: +978.43%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $39.42
Upside: +26.84%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.22
Upside: +1,293.44%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.25
Upside: +8,551.20%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $1.77
Upside: +5,945.20%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.30
Upside: +4,549.62%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.53
Upside: +4,279.08%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.22
Upside: +1,836.94%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.05
Upside: +197.52%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.95
Upside: +687.32%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.39
Upside: +979.14%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $6.15
Upside: +241.46%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $3.79
Upside: +902.64%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.83
Upside: +4,713.48%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.55
Upside: +809.09%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $7.05
Upside: +1,517.02%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $2.63
Upside: +7,504.56%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $10.38
Upside: +217.92%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $17.30
Upside: +131.21%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $0.91
Upside: +4,275.89%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.80
Upside: +1,955.56%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $3.66
Upside: +774.32%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $10.98
Upside: +601.28%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.73
Upside: +9,489.04%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.45
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $13.03
Upside: +283.73%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $2.19
Upside: +1,406.85%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $9.41
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $6.18
Upside: +320.71%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $132.18
Upside: -78.82%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.27
Upside: +16,029.03%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $7.06
Upside: +197.45%